In June 2025, the NPPA issued a notification emphasizing the need for pharmaceutical companies to adhere strictly to quality standards for non-scheduled drugs, including glucosamine. This directive aims to ensure the safety and efficacy of pharmaceutical products in the Indian market.
In August 2025, the DGFT streamlined the export NOC process for pharmaceutical products, reducing the processing time by 30%. This improvement facilitates faster export approvals, benefiting Indian exporters of glucosamine.
In October 2025, the WHO updated its Good Manufacturing Practices guidelines, incorporating more stringent quality control measures. Indian manufacturers exporting glucosamine are advised to align their processes with these updated guidelines to ensure compliance and maintain global market access.
In December 2025, the EMA initiated a review of glucosamine-containing medicinal products to reassess their benefit-risk profile. This ongoing review may impact the regulatory status of glucosamine products in the EU, and exporters should monitor developments closely.
In February 2026, the FDA issued a draft guidance document outlining new labeling requirements for dietary supplements, including glucosamine. The proposed changes aim to enhance consumer information and safety, and stakeholders are encouraged to provide feedback during the consultation period.
These developments underscore the dynamic nature of the regulatory landscape for glucosamine products. Indian exporters must remain vigilant and adaptable to navigate these changes effectively and maintain their competitive edge in the global market.
